Abstract
Patient care relies heavily on standardized tests performed in hospital laboratories, typically including clinical chemistry, pathology and microbiology. With the introduction of personalized medicine tremendous efforts have been made to identify new biomarkers of disease with various omics technologies, often including mass spectrometry. In order to validate new biomarkers and perform clinical studies high quality biobank samples are of key importance. In this editorial different aspects of mass spectrometry in future personalized medicine are discussed.
Cite
CITATION STYLE
Malm, J., & Marko‐Varga, G. (2016). Clinical protein science developments for patient monitoring in hospital central laboratories. Clinical and Translational Medicine, 5(1). https://doi.org/10.1186/s40169-016-0127-0
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.